Genprex (GNPX) Corporate Presentation from NobleCon18Research, News and Market Data on GenprexNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌


6/22/2026
Health
Release – EverythingALS to Host NeuroSense in a Community Event Named: PrimeC – Connecting the Dots
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that EverythingALS will host a conversation built around a look...
5 min read
‌


6/22/2026
Health
Release – Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented in oral and poster...
9 min read
‌


6/22/2026
Basic Materials
Resolution Minerals Ltd (RLMLF) – Resolution Joins U.S. Defense Consortium
Strengthening its strategic position. Resolution Minerals has been admitted into the U.S. Defense Industrial Base Consortium (DIBC), a Department of Defense-supported network focused on strengthening critical supply chains and industrial capabilities....
2 min read
‌


6/22/2026
Health
MAIA Biotechnology (MAIA) – Stream Of Clinical Milestones Reported In June Shows Ateganosine Progress
Strong Progress Reported In Both Clinical Trials. MAIA currently has two clinical trials in progress. Both trials are testing the combination of ateganosine (aka THIO) and the checkpoint inhibitor cemiplimab (Libtayo,...
2 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.